EA201692254A1 - Иммуномодулирующие прогениторные (имп) клетки - Google Patents

Иммуномодулирующие прогениторные (имп) клетки

Info

Publication number
EA201692254A1
EA201692254A1 EA201692254A EA201692254A EA201692254A1 EA 201692254 A1 EA201692254 A1 EA 201692254A1 EA 201692254 A EA201692254 A EA 201692254A EA 201692254 A EA201692254 A EA 201692254A EA 201692254 A1 EA201692254 A1 EA 201692254A1
Authority
EA
Eurasian Patent Office
Prior art keywords
imp
cells
progenative
immunomodulating
therapy
Prior art date
Application number
EA201692254A
Other languages
English (en)
Other versions
EA034083B1 (ru
Inventor
Аджан Реджинальд
Мартин Джон Эванс
Сабена Султан
Original Assignee
Селл Терапи Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Селл Терапи Лимитед filed Critical Селл Терапи Лимитед
Publication of EA201692254A1 publication Critical patent/EA201692254A1/ru
Publication of EA034083B1 publication Critical patent/EA034083B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0625—Epidermal cells, skin cells; Cells of the oral mucosa
    • C12N5/0633—Cells of secretory glands, e.g. parotid gland, salivary glands, sweat glands, lacrymal glands
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0665—Blood-borne mesenchymal stem cells, e.g. from umbilical cord blood
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/02—Atmosphere, e.g. low oxygen conditions
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/70—Undefined extracts
    • C12N2500/80—Undefined extracts from animals
    • C12N2500/84—Undefined extracts from animals from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
    • C12N2502/115—Platelets, megakaryocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/13—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells
    • C12N2506/1346—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells from mesenchymal stem cells
    • C12N2506/1353—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells from mesenchymal stem cells from bone marrow mesenchymal stem cells (BM-MSC)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)

Abstract

Настоящее изобретение относится к иммуномодулирующим прогениторным (ИМП) клеткам и их применению в терапии.
EA201692254A 2014-06-12 2015-06-09 Иммуномодулирующие прогениторные (имп) клетки EA034083B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1410504.3A GB201410504D0 (en) 2014-06-12 2014-06-12 Immuno-modulaltory progenitor (IMP) cell
PCT/GB2015/051673 WO2015189587A1 (en) 2014-06-12 2015-06-09 Immuno-modulatory progenitor (imp) cell

Publications (2)

Publication Number Publication Date
EA201692254A1 true EA201692254A1 (ru) 2017-06-30
EA034083B1 EA034083B1 (ru) 2019-12-25

Family

ID=51266501

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201692254A EA034083B1 (ru) 2014-06-12 2015-06-09 Иммуномодулирующие прогениторные (имп) клетки

Country Status (24)

Country Link
US (2) US12029763B2 (ru)
EP (2) EP2984163B1 (ru)
JP (2) JP6185657B2 (ru)
KR (2) KR20160029092A (ru)
CN (1) CN105473711A (ru)
AU (1) AU2015273271B2 (ru)
CA (1) CA2951492C (ru)
CY (1) CY1119093T1 (ru)
DK (1) DK2984163T3 (ru)
EA (1) EA034083B1 (ru)
ES (1) ES2622397T3 (ru)
GB (1) GB201410504D0 (ru)
HK (1) HK1219504A1 (ru)
HR (1) HRP20170657T1 (ru)
HU (1) HUE033392T2 (ru)
IL (2) IL249298B (ru)
LT (1) LT2984163T (ru)
MA (1) MA38860B1 (ru)
MY (1) MY181994A (ru)
PL (1) PL2984163T3 (ru)
PT (1) PT2984163T (ru)
SG (1) SG11201610355PA (ru)
WO (1) WO2015189587A1 (ru)
ZA (1) ZA201608402B (ru)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201513996D0 (en) * 2015-08-07 2015-09-23 Cell Therapy Ltd Immuno-oncology mesodermal progenitor (IOMP) cell
WO2017168170A1 (en) * 2016-03-31 2017-10-05 Cell Therapy Limited Immuno-modulatory progenitor (imp) cell expressing one or more of cd3, cd3e, cd8, cd8b, cd4, cd5, cd6 and cd7
US11179420B2 (en) * 2016-04-27 2021-11-23 Rohto Pharmaceutical Co., Ltd. Method for treating a disease, comprising administering mesenchymal stem cells or culture supernatant thereof to a subject
CN106267161A (zh) * 2016-09-30 2017-01-04 广州赛莱拉干细胞科技股份有限公司 一种干细胞制剂及其制备方法和应用
CN107184602B (zh) * 2017-06-01 2020-06-30 刘未斌 一种治疗肿瘤的药物组合
US11773376B2 (en) 2017-07-13 2023-10-03 National University Corporation Tokyo Medical And Dental University Artificial tendon or ligament tissue produced using three-dimensional mechanosignaling cell culture system
CN108660203A (zh) * 2018-05-18 2018-10-16 大连医科大学附属第医院 Cxcr2基因在心脏相关疾病中的用途
CN111971296A (zh) * 2018-05-30 2020-11-20 韩国亿诺生物有限公司 包含cd300e抑制剂作为活性成分的用于预防或治疗癌症的药物组合物
AU2019283518A1 (en) * 2018-06-05 2021-01-14 Medipost Co., Ltd. Pharmaceutical composition comprising mesenchymal stem cells as effective ingredient for prevention or treatment of inflammatory disease
WO2020148520A1 (en) 2019-01-15 2020-07-23 Cell Therapy Limited Mesodermal killer (mk) cell
GB201900554D0 (en) 2019-01-15 2019-03-06 Cell Therapy Ltd Mesodermal killer (mk) cell
CN110314173A (zh) * 2019-07-17 2019-10-11 中国医科大学附属第一医院 一种用于治疗骨关节炎的细胞制剂及其制备方法
US20220387668A1 (en) * 2019-11-07 2022-12-08 Massachusetts Eye And Ear Infirmary Cultivated Autologous Limbal Epithelial Cell (CALEC) Transplantation
WO2024080661A1 (ko) * 2022-10-12 2024-04-18 (주) 엘피스셀테라퓨틱스 신규한 혈관 형성 줄기세포
WO2024078729A1 (en) * 2022-10-14 2024-04-18 University College Cork - National University Of Ireland, Cork Placenta expressed proteins for use in the treatment of tendon injury

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8801537D0 (sv) 1988-04-26 1988-04-26 Ellco Food Ab Cellodlingsmedium samt forfarande for dess framstellning
US8663987B2 (en) 2008-05-28 2014-03-04 Ramot At Tel-Aviv University Ltd. Mesenchymal stem cells for the treatment of CNS diseases
US20120269779A1 (en) 2009-10-30 2012-10-25 Allocure, Inc. Mesenchymal stromal cell populations and methods of using same
EP2506867B1 (en) * 2009-12-02 2014-10-08 Cardio3 Biosciences S.A. Pharmaceutical compositions for the stimulation of stem cells.
US20130189741A1 (en) * 2009-12-07 2013-07-25 Cellscript, Inc. Compositions and methods for reprogramming mammalian cells
WO2012052911A1 (en) 2010-10-22 2012-04-26 Nokia Corporation Method and apparatus for co-operative reception for network controlled device to device
PT2729562T (pt) 2011-07-06 2018-07-18 Cell Therapy Ltd Células progenitoras de linhagem mesodérmica
ES2730984T3 (es) 2011-11-23 2019-11-13 Cell Therapy Ltd Gel de lisado de plaquetas
US9682104B2 (en) * 2012-01-26 2017-06-20 Jadi Cell Llc Lyophilized platelet lysates
US9670457B2 (en) 2012-05-08 2017-06-06 Stem Cell Reserve Lp Stem cells and matrix from cord tissue

Also Published As

Publication number Publication date
US20170080029A1 (en) 2017-03-23
EP2984163B1 (en) 2017-02-01
ZA201608402B (en) 2019-04-24
NZ727129A (en) 2021-02-26
JP6185657B2 (ja) 2017-08-23
WO2015189587A1 (en) 2015-12-17
KR20160029092A (ko) 2016-03-14
CN105473711A (zh) 2016-04-06
LT2984163T (lt) 2017-05-10
IL249298B (en) 2018-11-29
GB201410504D0 (en) 2014-07-30
JP2016525342A (ja) 2016-08-25
MY181994A (en) 2021-01-18
IL249298A0 (en) 2017-02-28
KR20180004319A (ko) 2018-01-10
MA38860A (fr) 2016-02-17
JP2017200474A (ja) 2017-11-09
EA034083B1 (ru) 2019-12-25
AU2015273271B2 (en) 2020-12-17
HRP20170657T1 (hr) 2017-06-30
CY1119093T1 (el) 2018-01-10
EP3211069A1 (en) 2017-08-30
CA2951492A1 (en) 2015-12-17
EP2984163A1 (en) 2016-02-17
DK2984163T3 (en) 2017-05-08
SG11201610355PA (en) 2017-01-27
ES2622397T3 (es) 2017-07-06
CA2951492C (en) 2022-12-06
US12029763B2 (en) 2024-07-09
US20190142869A1 (en) 2019-05-16
IL262827A (en) 2018-12-31
MA38860B1 (fr) 2017-09-29
HUE033392T2 (en) 2017-12-28
PT2984163T (pt) 2017-05-09
HK1219504A1 (zh) 2017-04-07
PL2984163T3 (pl) 2017-08-31
AU2015273271A1 (en) 2016-12-22

Similar Documents

Publication Publication Date Title
EA201692254A1 (ru) Иммуномодулирующие прогениторные (имп) клетки
IL267129A (en) New T-cell receptors and immunotherapy using them
IL253248A0 (en) Natural killer cells and their uses
EA201892386A1 (ru) Химерные нейротоксины
IL258666A (en) Natural killer cells and ilc3 cells and their use
DK3143134T3 (da) Modificerede, naturlige dræberceller og anvendelser deraf
DK3253865T3 (da) Fremgangsmåder til forbedring af virkningen af terapeutiske immunceller
EA201690280A1 (ru) Композиции и способы, относящиеся к выделенным эндофитам
TW201613966A (en) SynTac polypeptides and uses thereof
NZ733055A (en) Anti-c10orf54 antibodies and uses thereof
EA201692425A1 (ru) Модифицированные биополимеры и способы их получения и использования
EA201692529A1 (ru) Способы и композиции для лечения расстройств с использованием фоллистатиновых полипептидов
EA201692552A1 (ru) МОДИФИЦИРОВАННЫЕ МЕНИНГОКОККОВЫЕ ПОЛИПЕПТИДЫ fHbp
EA201691429A1 (ru) МОДИФИЦИРОВАННЫЕ МЕНИНГОКОККОВЫЕ ПОЛИПЕПТИДЫ fHbp
PH12017500836A1 (en) Transdermal formulations
IL259202A (en) Modified immune cells and their use
EA201890439A1 (ru) ИММУНООНКОЛОГИЧЕСКАЯ МЕЗОДЕРМАЛЬНАЯ КЛЕТКА-ПРЕДШЕСТВЕННИК (ioMP-КЛЕТКА)
MX2016004802A (es) Anticuerpos anti-r-espondina (anti-rspo) y metodos de uso.
EP3158025A4 (en) N-fluoroalkyl-substituted dibromonaphthalene diimides and their use as semiconductor
DK3498000T3 (da) MRS-konfiguration i to niveauer
EA201590615A1 (ru) Стимулирующие лактацию композиции на основе фосфатидилсерина
IL267131A (en) Novel t cell receptors and immune therapy using the same
GB201616232D0 (en) Novel cell line and uses thereof
DK3313870T3 (da) Aml-antigener og anvendelser deraf
EA202090225A3 (ru) Модифицированные менингококковые полипептиды fhbp

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG TJ TM